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The sensitivity to 5-fluorouracil (5-FU) has been reported to be associated with target molecule thymidylate synthase (TS),
fluoropyrimidine-metabolising enzymes such as orotate phosphoribosyltransferase (OPRT), and dihydropyrimidine dehydrogenase
(DPD). We performed an immunohistochemical study on the clinical significance of TS, OPRT, and DPD expression using 151
resected non-small-cell lung cancer (NSCLC) patients postoperatively treated with a combination of tegafur and uracil (UFT). Eighty-
two carcinomas were TS-positive, 105 carcinomas were OPRT-positive, 68 carcinomas were DPD-positive. No correlation was
observed in the HSCORE between the TS and OPRT expression (r¼0.203), between the TS and DPD expression (r¼0.098), or
between the OPRT and DPD expression (r¼0.074). Regarding the survival of NSCLC patients treated with UFT, the 5-year survival
rate of patients with TS-negative tumours was significantly higher than that with TS-positive tumours (P¼0.0133). The 5-year survival
rate of patients with OPRT-positive stage II to III tumours was significantly higher than that with OPRT-negative stage II to III tumours
(P¼0.0145). In addition, the 5-year survival rate of patients with DPD-negative tumours was also significantly higher than that with
DPD-positive tumours (P¼0.0004). A Cox multivariate regression analysis revealed the TS status (hazard ratio 2.663; P¼0.0003),
OPRT status (hazard ratio 2.543; P¼0.0005), and DPD status (hazard ratio 2.840; Po0.0001) to all be significant prognostic factors
for the survival of resected NSCLC patients postoperatively treated with UFT.
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Lung cancer is one of the most common cancers and the major
cause of cancer-related death in North America, Europe, and Japan
(Cersosimo, 2002). Non-small-cell lung cancer (NSCLC) comprises
about 75% of all lung cancers. The majority of NSCLC patients
have locally advanced stage III or metastatic stage IV disease at
diagnosis. In addition, even in the early stage, some NSCLC
patients may experience recurrence after surgery. Therefore, new
therapeutic strategies are required to improve the clinical outcome
of NSCLC patients.
Both experimental and clinical studies based on the molecular
biology have revealed many molecules to affect various biological
behaviors of malignant tumours including NSCLCs. To improve
the treatment of NSCLC patients, it is important to design an
optimal therapeutic strategy according to tumour biology (Huang
et al, 2005). Therefore, the selection of effective adjuvant therapies
based on biomarkers associated with tumour biology, such as
made-to-order chemotherapy, is considered to be an effective
strategy for NSCLC patients (Rosell et al, 2003; Vokes and Choy,
2003). Thus, the development of highly specific and responsive
sensitivity tests for anticancer agents is important to be able to
predict the response to an anticancer agent before using it for
treatment. Recent experimental and clinical studies have reported
several molecular targeted therapies, such as 5-fluorouracil (5-FU)-
derived agents against thymidylate synthase (TS) (Rustum et al,
1997), Gefitinib or Erlotinib against epidermal growth factor
receptor (Mitsudomi et al, 2005), and Bevacizumab against
vascular endothelial growth factor-A (Johnson et al, 2004).
Among them, 5-FU-derived agents have been widely used in the
treatment of various human cancers, including NSCLCs (Wada
et al, 1996; Kato et al, 2004), colorectal cancers (Macdonald and
Astrow, 2001), and gastric cancers (Takiuchi and Ajani, 1998),
since its introduction into clinical practice more than 40 years ago.
Clinical studies have reported their sensitivity to be associated with
the target molecule TS (Rustum et al, 1997), fluoropyrimidine-
metabolising enzymes such as orotate phosphoribosyltransferase
(OPRT) (Peters et al, 1986), and the 5-FU-catabolitic enzyme such
as dihydropyrimidine dehydrogenase (DPD) (Beck et al, 1994).
However, there were only a few clinical studies on the
simultaneous evaluations of these biomarkers to evaluate 5-FU
sensitivity (Isshi et al, 2002; Fujii et al, 2003; Ichikawa et al, 2003a).
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sTherefore, we performed a clinical study on the clinical
significance of TS, OPRT, and DPD expression for the treatment
of resected NSCLC patients who were postoperatively treated with
oral 5-FU derivatives, UFT (a combination of tegafur and uracil,
Taiho Pharmaceutical Co., Tokyo, Japan) (Wada et al, 1996; Kato
et al, 2004).
MATERIALS AND METHODS
Clinical characteristics of patients
From January 1995 to December 2000, consecutive NSCLC patients
who underwent surgery and were postoperatively treated with
UFT, at the Second Department of Surgery, Faculty of Medicine,
Kagawa University, were studied. This study was approved by the
institutional review board of Kagawa University (14-7, a clinical
study of biological markers in NSCLCs) and signed informed
consent was obtained from each patient. Tumour node metastasis
staging designations were made according to the postsurgical
pathological international staging system (Mountain, 1997). In
total, 151 patients with lung cancer up to stage III were
investigated (Table 1). They included 62 patients with stage I
NSCLCs, 28 patients with stage II NSCLCs, and 61 patients with
stage III NSCLCs. The patients’ clinical records and histopatho-
logical diagnoses were fully documented. This report includes
follow-up data as of 31 October 2005. The median follow-up period
for all patients was 65.7 months.
Regarding the methods for a surgical resection, a pneumonect-
omy was performed in 14 patients with stage II to III NSCLCs. A
lobectomy was performed in 123 patients; in 48 patients with stage
I NSCLCs, in 26 patients with stage II NSCLCs, and in 49 patients
with stage III NSCLCs. A segmentectomy was performed in four
patients with stage I NSCLCs, and a wedge resection was
performed in 10 patients with stage I NSCLCs. Platinum-based
chemotherapy using mitomycin/vinblastin/cisplatin or carboplatin/
paclitaxel was performed in 79 patients with stage II to III
NSCLCs; neoadjuvant chemotherapy in 39 patients, and post-
operative adjuvant chemotherapy in 40 patients with nodal
metastases. Radiation therapy was performed in 24 patients; in
17 patients with T3 or T4 status and in seven patients with
mediastinal lymph node metastases. The oral administration of
UFT (300–400mgday
 1body
 1) was started within 1 month after
surgery. UFT was administered for 2 years if there was no
recurrence of carcinomas. In patients with recurrences, UFT was
given until its oral administration became impossible.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue was cut into 4-mm
sections and mounted on poly-L-lysine-coated slides. The sections
were deparaffinised and rehydrated. The slides were then heated
in a microwave for 10min in a 10-mmoll
 1 citrate buffer solution at
pH 6.0, and cooled to room temperature for 20min. After
quenching the endogenous peroxidase activity with 0.3% H2O2
(in absolute methanol) for 30min, the sections were treated for 2h
at room temperature with 5% bovine serum albumin to block
nonspecific staining. Duplicate sections were incubated overnight
with the primary specific antibodies detecting TS (rabbit IgG,
diluted at 1:500), OPRT (rabbit IgG, diluted at 1:1000), and DPD
(rabbit IgG, diluted at 1:500) (Huang et al, 2000). The slides were
then incubated for 1h with biotinylated anti-rabbit IgG (Vector
Laboratories Inc., Burlingame, CA, USA). The sections were
incubated with the avidin–biotin–peroxidase complex (Vector
Laboratories Inc.) for 1h, and antibody binding was visualised with
3,3’-diaminobenzidine tetrahydrochloride. Finally, the sections
were lightly counterstained with Mayer’s hematoxylin. The human
colon cancer cell line DLD-1/FrUrd was used as a positive control
for the staining of TS. Sections of resected lung tumours to express
OPRT were used as positive controls for the staining of OPRT. The
human pancreatic cancer cell line MIAPaCa-2 was used as a
positive control for the staining of DPD. A rabbit IgG was used as a
negative control during each run of immunohistochemical staining.
All of the immunostained sections were reviewed by two authors
(J Nakano and M Ueno) who had no knowledge of the patients’
clinical status. In cases of multiple areas of low intensity, five areas
selected at random were scored. In sections where all of the
staining appeared to be intense, one random field was selected. At
least 200 tumour cells were scored per  40 field. All sections were
scored in a semiquantitative manner according to a previously
described method, which reflects both the intensity and percentage
of cells staining at each intensity (McCarty et al, 1986). Intensity
was classified as 0 (no staining), þ1 (weak staining), þ2 (distinct
staining), or þ3 (very strong staining). A value designated as the
‘HSCORE’ was obtained for each slide by using the following
Table 1 Patient demographics
Patient characteristics Number %
Total number of patients 151 100.0
Age (years)
Median 64
Range 35–76
Gender
Male 104 68.9
Female 47 31.1
Smoking habitus
Nonsmoker 51 33.8
Smoker 100 66.2
ECOG performance status
0 85 56.3
1 57 37.7
2 9 6.0
Pathological stage
I 62 41.1
II 28 18.5
III 61 40.4
Differentiation
Well 46 30.5
Moderately 54 35.7
Poorly 51 33.8
Histology
Adenocarcinoma 84 55.6
Squamous cell carcinoma 56 37.1
Large cell carcinoma 11 7.3
Method of surgical resection
Pneumonectomy 14 9.3
Lobectomy 123 81.5
Segmentectomy 4 2.6
Wedge resection 10 6.6
Chemothrapy
Platinum-based chemotherapy 79 52.3
Neoadjuvant MVP 30 19.8
Neoadjuvant CBDCA/PTX 9 6.0
Postoperative adjuvant MVP 26 17.2
Postoperative adjuvant CBDCA/PTX 14 9.3
UFT 151 100.0
Radiotherapy 24 15.9
CBDCA/PTX¼carboplatin/paclitaxel; ECOG¼Eastern Cooperative Oncology
Group; MVP¼mitomycin/vinblastin/cisplatin; UFT¼a combination of tegafur and
uracil.
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salgorithm: HSCORE¼
P
(I PC), where I and PC represent the
staining intensity and the percentage of cells that stain at each
intensity, respectively. And the corresponding HSCOREs were
calculated separately. Concerning TS expression, when the
HSCORE of TS in a given specimen was X30, the sample was
classified as TS-positive, the same as reported previously (Huang
et al, 2000). Concerning OPRT expression, the sample was
classified as OPRT-positive when the HSCORE of OPRT in a
given specimen was X30, because the cutoff line of 30 showed the
most significant association with a survival difference. Concerning
DPD expression, when the HSCORE of DPD in a given specimen
was X50, the sample was classified as DPD-positive, the same as
reported previously (Huang et al, 2000).
Statistical analysis
The statistical differences in the expression of each biological
marker in relation to various clinical and pathological parameters
were assessed by the w
2-test. Overall survival was defined as the
time from treatment initiation (surgical resection, chemotherapy,
or radiation) to the date of death from any cause. The Kaplan–
Meier method was used to estimate the probability of overall
survival as a function of time, and differences in the survival of
subgroups of patients were compared by using Mantel’s log-rank
test. A multivariate analysis was performed using the Cox
regression model to study the effects on survival (Cox, 1972). All
P-values were based on two-tailed statistical analysis, and a P-value
o0.05 was considered to indicate statistical significance.
RESULTS
Clinical significance of intratumoural TS expression in
NSCLCs treated with UFT
The intratumoural TS expression appeared in a cytoplasmic
staining pattern (Figure 1A and 1B). Of the 151 NSCLCs we
studied, 82 carcinomas (54.3%) were TS-positive, and 69
carcinomas (45.7%) were TS-negative (Table 2). The frequency
of TS-positive tumours was significantly higher in squamous cell
carcinomas than in adenocarcinomas (69.6 vs 42.9%, P¼0.0063).
However, there was no difference in the TS status according to
tumour status, nodal status, pathological stage, tumour differ-
entiation, or neoadjuvant chemotherapy.
Regarding the survival of NSCLC patients treated with UFT, the
5-year survival rate of patients with TS-negative tumours was
significantly higher than that with TS-positive tumours (69.1 vs
44.7%, P¼0.0133, Figure 2A). Regarding the pathological stage,
the 5-year survival rate of patients with TS-negative stage I
tumours was significantly higher than that with TS-positive stage I
tumours (86.2 vs 63.2%, P¼0.0426, Figure 2B). In addition, the 5-
year survival rate of patients with TS-negative stage II to III
tumours was also significantly higher than that with TS-positive
stage II to III tumours (55.6 vs 27.9%, P¼0.0259, Figure 2C).
Clinical significance of intratumoural OPRT expression in
NSCLCs treated with UFT
The intratumoural OPRT expression appeared in a cytoplasmic
staining pattern (Figure 1C and D). Of the 151 NSCLCs, 105
carcinomas (69.5%) were OPRT-positive, and 46 carcinomas
(30.5%) were OPRT-negative (Table 2). There was no difference
in the OPRT status according to tumour histology, tumour status,
nodal status, pathological stage, tumour differentiation, or
neoadjuvant chemotherapy.
Regarding the survival of NSCLC patients treated with UFT,
there was no significant difference in the 5-year survival rates
between patients with OPRT-positive tumours and patients with
OPRT-negative tumours (60.6 vs 48.0%, Figure 3A). Regarding the
pathological stage, there was also no significant difference in the
5-year survival rates of patients with stage I NSCLCs, according to
the OPRT status (Figure 3B). However, among locally advanced
stage II to III, the 5-year survival rate of patients with OPRT-
positive tumours was significantly higher than that with OPRT-
negative tumours (50.8 vs 25.0%, P¼0.0145, Figure 3C).
Clinical significance of intratumoural DPD expression in
NSCLCs treated with UFT
The intratumoural DPD expression appeared in a cytoplasmic
staining pattern (Figure 1E and 1F). Of the 151 NSCLCs, 68
carcinomas (45.0%) were DPD-positive, and 83 carcinomas
(55.0%) were DPD-negative (Table 2). There was no difference in
the DPD status according to tumour histology, tumour status,
nodal status, pathological stage, tumour differentiation, or
neoadjuvant chemotherapy.
Regarding the survival of NSCLC patients treated with UFT, the
5-year survival rate of patients with DPD-negative tumours was
significantly higher than that with DPD-positive tumours (66.6 vs
42.6%, P¼0.0004, Figure 4A). Regarding the pathological stage,
the 5-year survival rate of patients with DPD-negative stage I
tumours was significantly higher than that with DPD-positive stage
I tumours (79.8 vs 63.0%, P¼0.0391, Figure 4B). In addition, the
5-year survival rate of patients with DPD-negative stage II to III
tumours was also significantly higher than that with DPD-positive
stage II to III tumours (52.4 vs 31.0%, P¼0.0174, Figure 4C).
Prognostic factors of resected NSCLC patients treated with
UFT
No correlation was observed in the HSCORE between the TS
expression and OPRT expression (r¼0.203), between the TS
expression and DPD expression (r¼0.098), or between the OPRT
expression and DPD expression (r¼0.074). A Cox multivariate
regression analysis of the prognostic variables for resected NSCLC
patients treated with UFT is shown in Table 3. Five variables,
including the TS status (hazard ratio 2.663; P¼0.0003), OPRT
status (hazard ratio 2.534; P¼0.0005), DPD status (hazard ratio
2.840; Po0.0001), pathological stage (hazard ratio 1.908;
Po0.0001), and the methods of surgical resection (a pneumo-
nectomy vs other methods)(hazard ratio 2.555; P¼0.0242), were
demonstrated to be significant prognostic factors for survival of
resected NSCLC patients postoperatively treated with UFT.
DISCUSSION
5-Fluorouracil is one of the most widely used antitumour
chemothrapeutic agents for the treatment of a variety of human
malignancies, especially in terms of the patient quality of life and
economy (Wada et al, 1996). In fact, prospective randomised
clinical studies have found the administration of UFT to be an
effective adjuvant chemotherapy for NSCLC patients (Wada et al,
1996; Kato et al, 2004). On the other hand, many experimental and
clinical studies have also revealed the 5-FU sensitivity to be
affected by several biomarkers, such as its target molecule TS
(Rustum et al, 1997), several fluoropyrimidine metabolising
enzymes (Peters et al, 1986; Peters et al, 1991), and DPD, an
enzyme of 5-FU catabolism (Beck et al, 1994).
First of all, regarding TS, its activity is necessary for cell
proliferation because it catalyses the conversion of deoxyuridine-
50-monophosphate to deoxythymidine-50-monophosphate, an
essential step in DNA synthesis. After 5-FU is converted into 5-
fluoro-20-deoxyuridine 50-monophosphate (FdUMP), this activated
molecule forms a tight-binding complex with TS and 5,10-
methylene-tetrahydrofolate, thus resulting in the inhibition of
the TS activity (Rustum et al, 1997). Thymidylate synthase is
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stherefore a target molecule of 5-FU. In addition, previous studies
have reported that the regulation of the TS expression was affected
by several mechanisms, including the polymorphism of the
tandem repeated sequences in the promoter enhancer region of
its gene and the genetic amplification of 18p (Horie et al, 1995;
Hidaka et al, 2003).
In fact, many previous studies have reported the intratumoural
TS expression to be associated with tumour proliferation (Naval-
gund et al, 1980; Nakagawa et al, 2004), the responsiveness to 5-FU
(Johnston et al, 1995; Yeh et al, 1998). In addition, the over-
expression of TS is reported to be associated with a poor prognosis
of many cancer patients treated with 5-FU, including NSCLCs
(Huang et al, 2000) and gastrointestinal cancers (Lenz et al,1 9 9 6 ) .
The present study in a relatively large number of patients treated
with UFT also revealed that the survival of patients with TS-negative
tumours was significantly better than that with TS-positive tumours.
Furthermore, the significant differences in the survival of patients
were observed in stage I cases as well as in locally advanced stage II
to III cases. These results might be due to not only the
responsiveness to 5-FU but also tumour proliferation (Nakagawa
et al, 2004; Huang et al, 2005). In fact, recent studies have found that
TS exhibits an oncogene-like activity (Rahman et al,2 0 0 4 ) .I n
addition, the overexpression of TS itself is an independent factor for
a poor prognosis in NSCLC patients (Huang et al,2 0 0 5 ) .
Figure 1 Immunohistochemical staining of human NSCLC tissues (original magnification,  100). (A, B) Carcinoma with positive and negative TS
expression, (C, D) carcinoma with positive and negative OPRT expression, (E, F) carcinoma with positive and negative DPD expression.
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sSecondly, because 5-FU itself is a prodrug which requires its
intracellular conversion, interindividual variation in the activity of
fluoropyrimidine-metabolising enzymes can affect the activation of
5-FU. In general, phosphorylation is necessary to activate 5-FU by
one or more of three pathways (Peters et al,1 9 8 6 ;P e t e r set al, 1991).
Among them, OPRT is considered to be a major enzyme in the 5-FU
conversion, directly to 5-fluorouridine 50-monophosphate (FUMP)
leading to the formation of FdUMP in the presence of 5-
phosphoribosyl-1-pyrophosphate as a cofactor (Shirasaka et al,
1993). Experimental studies using cell lines have revealed a
decreased expression and activity of OPRT to be associated with
resistance to 5-FU (Chung et al,2 0 0 0 ;M u r a k a m iet al, 2000).
Although the true mechanisms for the downregulation of OPRT
expression in human cancers are still unclear, an experimental study
has suggested the loss of 3q to be a genetic change responsible for
the decreased OPRT activity and acquired resistance to 5-FU
(Hidaka et al, 2003). Furthermore, the adenoviral-mediated
transduction of OPRT gene was reported to result in a marked
sensitisation of tumour cells to 5-FU cytotoxicity (Kanai et al, 1998).
Previous clinical studies also revealed the positive expression
and activity of OPRT to be associated with the responsiveness to
5-FU in a variety of human cancers, including colorectal cancers
(Isshi et al, 2002; Fujii et al, 2003; Ichikawa et al, 2003a;
Matsuyama et al, 2006) and bladder carcinomas (Mizutani et al,
2004). However, these studies were performed using relatively
small number of patients, and then were evaluated by biochemical
assays for OPRT enzyme activity or reverse transcriptional PCR
(RT–PCR) assays for OPRT gene expression. Biochemical assays
are difficult to perform in clinical use, and they need a large
volume of sample tissue. In the present study, we evaluated the
intratumoural OPRT expression by immunohistochemistry using
an anti-OPRT polyclonal antibody, obtained by immunising
rabbits with the OPRT peptide. The immunochemical detection
Table 2 Distribution of biomarkers in 151 NSCLC patients according to
clinicopathological characteristics
TS-positive OPRT-positive DPD-positive
Characteristics n (%) P-value (%) P-value (%) P-value
Smoking
Nonsmoker 51 52.0 0.4260 70.6 0.8411 54.9 0.1167
Smoker 100 58.8 69.0 40.0
Tumour status
T1, T2 102 56.9 0.3626 73.5 0.1240 40.2 0.1211
T3, T4 49 49.0 61.2 55.1
Nodal status
N0 88 48.9 0.1127 67.0 0.4319 38.6 0.0887
N1, N2 63 61.9 73.0 54.0
Pathological stage
Stage I 62 53.2 0.7905 66.1 0.4886 35.5 0.0757
Stage II 28 50.0 78.6 42.9
Stage III 61 57.4 68.9 55.7
Differentiation
Well 46 60.9 0.1888 65.2 0.4395 43.5 0.9338
Moderately 54 44.4 75.9 44.4
Poorly 51 58.8 66.7 47.1
Histology
Adenocarcinoma 84 42.9 0.0063 69.0 0.3170 47.6 0.5025
Squamous cell
carcinoma
56 69.6 76.8 39.3
Large cell
carcinoma
11 63.6 36.4 54.5
Neoadjuvant
chemotherapy
Neoadjuvant
MVP
30 60.0 0.3700 53.3 0.0943 50.0 0.6691
Neoadjuvant
CBDCA/PTX
9 33.3 77.8 33.3
Without
neoadjuvant
112 54.5 73.2 44.6
Total number of patients 151 54.3 69.5 45.0
CBDCA/PTX¼carboplatin/paclitaxel; MVP¼mitomycin/vinblastin/cisplatin; NSCLC¼
non-small-cell lung cancer.
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Figure 2 Overall survival of NSCLC patients treated UFT in relation to
TS status. (A) Total NSCLCs. (B) Stage I NSCLCs. (C) Stage II to III
NSCLC.
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susing this antibody was found to positively correlate with the
OPRT enzyme activity (Sakamoto et al, 2005), and immunohisto-
chemical assays are easy to perform in clinical use. Consequently,
the present study demonstrated the positive expression of OPRT to
be one of the significant factors for a good survival for resected
NSCLC patients postoperatively treated with UFT, especially in
advanced stage II to III. To our knowledge, the present study was
the first clinical report using immunohistochemistry, to demon-
strate the clinical significance of the OPRT expression in a
relatively large number of cancer patients treated with UFT. In fact,
a recent clinical study also revealed a positive OPRT activity to be
associated with a better prognosis in resectable colorectal cancer
patients treated with oral 5-FU (Ochiai et al, 2006).
On the other hand, regarding other pathways of 5-FU activation,
thymidine phosphatase (TP) is considered to not be important
because of the lack of its cofactor dRib-1-P at physiological
concentrations (Barankiewicz and Henderson, 1977). Conversely, high
TP concentration in conjunction with the normally low dRib-1-P drive
the reaction in the opposite direction (Ackland and Peters, 1999). In
fact, no difference was observed in the survivals of NSCLC patients
treated with UFT according to the intratumoural TP expression in our
pilot study by immunohistochemistry (data not shown).
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Figure 3 Overall survival of NSCLC patients treated UFT in relation to
OPRT status. (A) Total NSCLCs. (B) Stage I NSCLCs. (C) Stage II to III
NSCLC.
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Figure 4 Overall survival of NSCLC patients treated UFT in relation to
DPD status. (A) Total NSCLCs. (B) Stage I NSCLCs. (C) Stage II to III
NSCLC.
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sThird, due to the fact that 80–90% of the administered 5-FU is
degraded by DPD in humans, the first and rate-limiting enzyme of
5-FU catabolism, only a small part of the 5-FU is activated (Fischel
et al, 1995). As a result, 5-FU degradation generally occurs in all
tissues, including tumour tissues, but it reaches its highest level
in the liver (Ho et al, 1986). In fact, a congenital deficiency of DPD
can result in severe life-threatening toxicity when 5-FU is
administered (Wei et al, 1996). In contrast, many experimental
studies have demonstrated the intratumoural DPD activity to affect
the resistance to 5-FU (Beck et al, 1994; Ishikawa et al, 1999).
Previous clinical studies also found an overexpression of DPD in
tumour cells to be associated with 5-FU resistance (Higashiyama
et al, 2001) and a poor prognosis in many cancer patients treated
with 5-FU, including NSCLCs (Huang et al, 2000; Nakagawa et al,
2002), colorectal cancers (Ichikawa et al, 2003b), and breast
cancers (Horiguchi et al, 2004). Although several clinical studies
reported DPD expression to not be associated with the survival of
cancer patients treated with 5-FU (Ikeguchi et al, 2002; Kornmann
et al, 2002; Hakamada et al, 2005), this discrepancy might be due
to the different types of 5-FU administration such as intravenous
infusion, the different antibody used, or the contamination of
intratumoural stromal cells.
Based on these facts about the biomarkers associated with
sensitivity to 5-FU, we thus considered a clinical study to
simultaneously evaluate the expressions of TS, OPRT, and DPD,
to be important for establishing the protocol of made-to-order
chemotherapy for NSCLC patients. Therefore, we performed the
present study using a relatively large number of patients treated
with UFT. Consequently, the intratumoural expressions of TS,
OPRT, and DPD were found to be independent of each other.
Furthermore, a Cox multivariate analysis demonstrated all the
intratumoural expressions of TS, OPRT, and DPD to be
independent prognostic factors for resected NSCLC patients
postoperatively treated with UFT. As a result, regarding the
biomarkers associated with sensitivity to 5-FU, the survival of
patients with TS-negative, OPRT-positive, and DPD-negative
NSCLCs, which appeared in 12.6% (19 of 151) in the present
study, was the highest among resected NSCLC patients treated with
UFT.
Besides these biomarkers associated with sensitivity to 5-FU, the
present study revealed that pathological stage and methods of
surgical resection (a pneumonectomy vs other methods) were also
independent prognostic factors for the resected NSCLC patients
treated with UFT. Previous clinical studies also demonstrated that
the survival of patients treated with a pneumonectomy is worse
than that of patients treated with other surgical methods (Rocco
et al, 1996; Ludwig et al 2005). On the other hand, regarding
chemotherapy, most of patients with locally advanced stage II to
III NSCLCs were treated with either neoadjuvant or postoperative
adjuvant platinum-based chemotherapy using mitomycin/vinblas-
tin/cisplatin or carboplatin/paclitaxel in the present study.
However, we found no difference in the survivals of patients
according to the platinum-based chemotherapy (data not shown).
In order to clarify the clinical significance of the platinum-based
chemotherapy for NSCLC patients, a randomised prospective
study should thus be performed. Furthermore, among the locally
advanced stage II to III cases, no difference was observed in the
survivals of patients according to radiotherapy in the present study
(data not shown). In fact, previous clinical studies also reported
that radiotherapy itself has less survival benefit for NSCLC patients
(Dautzenberg et al, 1999).
The efficacy of UFT is still lower in NSCLCs than in
gastrointestinal cancers. For one reason, NSCLCs are human
tumours with a high expression of DPD because DPD-positive
tumours occurred in 45% of NSCLCs in the present study.
Therefore, it is important to inhibit the DPD activity to improve
the responsiveness to 5-FU against DPD-positive NSCLCs.
Recently, S-1 (a combination of tegafur, gimeracil, and oteracil
potassium, Taiho) has been developed for clinical use (Chu et al,
2004; Ichinose et al, 2004). Gimeracil used in S-1 is a stronger
inhibitor for the intratumoural DPD activity than uracil used in
UFT. As a result, S-1 might be more effective for patients with
TS-negative, OPRT-positive, and DPD-positive NSCLCs, which
occurred in 15.9% (24 of 151) in the present study. Therefore,
patients with TS-negative and OPRT-positive NSCLCs, which
appeared in 28.5% (43 of 151) in the present study, could be
successfully treated by S-1 without evaluating the intratumoural
DPD activity. In order to develop and simplify the protocol of
made-to-order chemotherapy, a further randomised prospective
study using S-1 should thus be performed to evaluate this
possibility.
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